Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BA3182 · 1 trial · 1 indication
Phase 1 Part 1: Safety Profile of BA3182
Phase 1 Part 1: Safety Profile of BA3182
Phase 1 Part 2: Antitumor activity of BA3182
| Arm | Type | Description |
|---|---|---|
| BA3182 | EXPERIMENTAL | All Patients will receive BA3182 |
| Name | Type | Description |
|---|---|---|
| BA3182 | DRUG | Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM |
Inclusion Criteria: * Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma * Age ≥ 18 years * Adequate renal function * Adequate liver function * Adequate hematological function * Have an Eastern Cooperative Oncology Group (ECOG) performance status of...
BA3182 is an investigational small molecule being developed for the treatment of advanced adenocarcinoma, a type of cancer that arises from glandular tissue. It is currently being evaluated in a Phase 1 clinical trial in patients with this condition.
BA3182 targets ROR2, a transmembrane receptor tyrosine kinase. ROR2 is involved in cellular signaling pathways that can contribute to tumor growth and progression, making it a focus of therapeutic intervention in oncology.
BA3182 is being developed by BioAtla, Inc., a biotechnology company. BioAtla is conducting the clinical development of this investigational therapy for advanced adenocarcinoma.
BA3182 is currently in Phase 1 of clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in patients.
BA3182 is being studied in a Phase 1 clinical trial with the identifier NCT05808634. This trial is evaluating the drug in patients with advanced adenocarcinoma and is currently recruiting participants in the United States.